• Verovaccines upscales manufacturing processes of its yeast-based vaccines to industrial
scale
• This is an important milestone on the road to commercialization of this novel vaccine class
German vaccine specialist Verovaccines GmbH is on its way to industrial-scale production. To this end, a series of controlled fermentation studies were conducted, which revealed exceptionally high reproducibility of the life yeast production system (see Figure). Low variation from run to run is key to a reliable production system for biopharmaceutical products such as vaccines.
In addition, scale-up studies were initiated to move from the 5-liter laboratory scale to the industrial 300-1,000-liter scale. Together with two service providers, the company was able to successfully carry out this upscaling in just two fermentation runs. Already the first industrial run delivered a similar yield per liter as the lab scale and ran very stable from the beginning.
Managing Director Dr. Hanjo Hennemann: ‘Based on the latest reproducibility and upscaling results, we are confident that we can complete the establishment of key production steps as planned.’ Managing Director Prof. Sven-Erik Behrens adds, ‘Furthermore, we expect to be able to easily upscale other yeast-based vaccines derived from our platform.’
